



LMA International NV

26 May 2010

Announcement to the Singapore Exchange

LMA LICENSES LMA STONEBREAKER™ INTELLECTUAL PROPERTY

On 19 May 2010, LMA International NV ("LMA") signed an exclusive licence agreement with Cook Medical Inc ("Cook") to enable Cook to exploit the intellectual property, manufacture and sell the LMA StoneBreaker™ and related devices on a worldwide basis. The LMA StoneBreaker™ is a portable intra-corporeal contact lithotripter which effectively fragments stones in the urinary tract. The agreement, which is for a five year period, supersedes the distribution agreement with Cook announced in February 2009. LMA will now be able to focus on its core airway and anaesthesia business segment whilst generating an ongoing fixed royalty revenue stream from its Urology segment.

At the end of the five year licence agreement, Cook will have an option, should they complete the full term of the licence agreement, to acquire the intellectual property to LMA's urology devices for a nominal sum. Cook is a leader in developing healthcare devices with a global sales force in the urology field and is well placed to develop this product sector.

As a result of the signing of this agreement, LMA will work with Cook to transfer the manufacturing of the devices to one of Cook's facilities in the United States during the remainder of 2010. LMA's facility in Switzerland will cease manufacturing activities when the transition process has been completed. This transaction will not have a material impact on LMA's earnings per share or net tangible assets for the financial year ending 31 December 2010.

As part of this licence arrangement, LMA completed the purchase of the remaining 37.5% shares of LMA Urology Ltd ("LMAU") from Duliver International Ltd ("Duliver") on 18 May 2010. The consideration of US\$1.9 million was arrived at on the basis of arms length negotiation, taking into account the terms of the sale and purchase agreement with Duliver announced in February 2006 relating to the acquisition of the LMA StoneBreaker™. The transaction brings the total consideration for LMAU to US\$6.84 million. The acquisition of 37.5% of LMAU will not have a material impact on LMA's earnings per share or net tangible assets for the financial year ending 31 December 2010.

Lawrence Kinet, Group Chief Executive Officer of LMA, commented: "I am delighted to be able to announce these transactions which facilitate the completion of one element of our strategy, which is the exit from the Urology business whilst enabling the LMA StoneBreaker™ to be developed by Cook. This will permit LMA to redeploy resources to our airway and anaesthesia business."

None of the directors or controlling shareholders of LMA has any interest, direct or indirect, in the transactions.

ENDS

LMA International NV

Osprey House, Old Street, St. Helier, Jersey JE2 3RG, Channel Islands

About LMA

Incorporated in the Netherlands Antilles in 1998, LMA listed on the Mainboard of the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ laryngeal mask airway range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ laryngeal mask airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in the United States, Singapore, Germany, Italy and Australia. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA. For more information, visit www.lmanv.com.